CMS mandates 180-day Part D claims
CMS has mandated that Part D drug plans allow 180 days for filingclaims incurred between Jan. 1 and June 30. Problems withcoordination of benefits have required the reversal of claims andrebilling to the appropriate payer. Since a lack of information ledpharmacies to sometimes bill the wrong payer, they should not beheld to the usual 30- to 90-day timely billing standard, CMSconcluded.
CMS mandates 180-day Part D claims
CMS has mandated that Part D drug plans allow 180 days for filing claims incurred between Jan. 1 and June 30. Problems with coordination of benefits have required the reversal of claims and rebilling to the appropriate payer. Since a lack of information led pharmacies to sometimes bill the wrong payer, they should not be held to the usual 30- to 90-day timely billing standard, CMS concluded. The agency mandated the 180-day window after some Part D plans failed to create appropriate claims filing rules as CMS had requested.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
FDA Approves Lebrikizumab-lbkz for Moderate-to-Severe Atopic Dermatitis
September 16th 2024Lebrikizumab-lbks is a targeted treatment that addresses the root cause of atopic dermatitis; by reducing inflammation throughout the body, it can help alleviate the dry, itchy, and irritated skin that often characterizes the condition.
